Drugs.com Blog

The Official Drugs.com Blog

Q2 2013 Drug Sales Data Released: Humira Climbs and Posts Double-Digit Growth

August 8, 2013 By Carmen Fookes

The latest U.S. drug sales data has been released by Drugs.com. Since Q2 2012, Otuska’s antipsychotic Abilify and AstraZeneca’s acid reducer Nexium have held either the number one or two spot in top dollar sales. This quarter, both agents continue to maintain their stronghold; each post close to $1.5 billion in sales. Humira, AbbVie’s key tumor necrosis factor (TNF) blocker, climbs three notches and sees a double-digit gain for the quarter. Biogen Idec’s Avonex Pen and Avonex take a double hit this quarter and lose $187 million in sales.

View the data here…
https://www.drugs.com/stats/top100/sales

Filed Under: Business, Media, Statistics

Recent Posts

  • Green Gold April 30, 2019
  • Worshipping The Wine (or Beer) God or Godess April 23, 2019
  • No Easy Fix To The Opioid Crisis January 15, 2019
  • 2018: The Year for Blockbusters. December 26, 2018
  • How do I get my doctor to listen to me? December 18, 2018

Categories

  • Business
  • Commentary
  • Media
  • Mobile
  • Patient Safety
  • Site Upgrades
  • Statistics
  • Uncategorized

Copyright © 2023 Drugs.com - Return to Drugs.com